CG Oncology, Inc. (CGON)Healthcare | Biotechnology | Dallas, United States | NasdaqGS
74.34 USD
-4.67
(-5.911%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 73.91 -0.43 (-0.430%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 6 a.m. EDT
The stock is rallying hard in the short term, gaining over ten percent in the last two weeks, driven by positive trial results and analyst optimism. However, this momentum clashes with the reality of the business, which is burning cash and posting losses. Insiders are actively selling shares, a stark warning sign that contradicts the bullish analyst consensus. The valuation is detached from current performance, trading at a massive premium despite negative earnings. Because the price history covers only a single year, it is difficult to confirm whether the recent decline was a temporary setback or a structural issue. For now, the trade feels like a speculative gamble on a pipeline rather than a sound investment in a profitable company. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.099800 |
| AutoARIMA | 0.114886 |
| AutoETS | 0.114887 |
| MSTL | 0.117092 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 1.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.046 |
| Excess Kurtosis | -0.85 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.857 |
| Revenue per Share | 0.076 |
| Market Cap | 6,589,524,992 |
| Forward P/E | -24.61 |
| Beta | 0.23 |
| Website | https://cgoncology.com |
As of Aug. 22, 2026, 6 a.m. EDT: Speculators are pricing in high volatility with elevated implied volatility across expirations. While near-term puts indicate hedging against a potential correction, long-dated calls at strikes significantly above the current price suggest a belief in eventual recovery or approval milestones. The heavy put volume in October contrasts with the deep out-of-the-money call interest in January 2027.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.877276 |
| Address1 | 3,000 Pegasus Park Drive |
| Address2 | Suite 1640 |
| All Time High | 80.97 |
| All Time Low | 14.8 |
| Ask | 95.48 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 706,810 |
| Average Daily Volume3 Month | 985,738 |
| Average Volume | 985,738 |
| Average Volume10Days | 706,810 |
| Beta | 0.23 |
| Bid | 56.06 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 11.654 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 74.34 |
| Current Ratio | 22.219 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 78.155 |
| Day Low | 73.93 |
| Debt To Equity | 0.857 |
| Display Name | CG Oncology |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -249,663,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -22.31 |
| Enterprise To Revenue | 894.359 |
| Enterprise Value | 5,570,066,432 |
| Eps Current Year | -3.20456 |
| Eps Forward | -3.02065 |
| Eps Trailing Twelve Months | -2.69 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 72.5794 |
| Fifty Day Average Change | 1.7605972 |
| Fifty Day Average Change Percent | 0.024257533 |
| Fifty Two Week Change Percent | 187.7276 |
| Fifty Two Week High | 80.97 |
| Fifty Two Week High Change | -6.630005 |
| Fifty Two Week High Change Percent | -0.08188224 |
| Fifty Two Week Low | 26.245 |
| Fifty Two Week Low Change | 48.094994 |
| Fifty Two Week Low Change Percent | 1.8325392 |
| Fifty Two Week Range | 26.245 - 80.97 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,706,193,000,000 |
| Float Shares | 64,732,293 |
| Forward Eps | -3.02065 |
| Forward P E | -24.610596 |
| Free Cashflow | -113,709,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 142 |
| Fullday Change | -4.67001 |
| Fullday Change Percent | -5.91065 |
| Fullday Price | 73.91 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -161,535,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00228 |
| Held Percent Institutions | 1.1361 |
| Implied Shares Outstanding | 88,640,375 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-01-25 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas. |
| Long Name | CG Oncology, Inc. |
| Market | us_market |
| Market Cap | 6,589,524,992 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_115902660 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -224,375,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,007,908,047 |
| Number Of Analyst Opinions | 13 |
| Open | 78.15 |
| Operating Cashflow | -178,467,008 |
| Operating Margins | -74.67675 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 949 409 3700 |
| Post Market Change | -0.42999268 |
| Post Market Change Percent | -0.57841367 |
| Post Market Price | 73.91 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 79.01 |
| Price Eps Current Year | -23.19819 |
| Price Hint | 2 |
| Price To Book | 6.3789253 |
| Price To Sales Trailing12 Months | 1,058.0483 |
| Profit Margins | 0.0 |
| Quick Ratio | 21.776 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | -4.67001 |
| Regular Market Change Percent | -5.91065 |
| Regular Market Day High | 78.155 |
| Regular Market Day Low | 73.93 |
| Regular Market Day Range | 73.93 - 78.155 |
| Regular Market Open | 78.15 |
| Regular Market Previous Close | 79.01 |
| Regular Market Price | 74.34 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 612,555 |
| Return On Assets | -0.1767 |
| Return On Equity | -0.26405 |
| Revenue Per Share | 0.076 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 88,640,375 |
| Shares Percent Shares Out | 0.1269 |
| Shares Short | 11,248,462 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 12,105,610 |
| Short Name | CG Oncology, Inc. |
| Short Percent Of Float | 0.1292 |
| Short Ratio | 12.96 |
| Source Interval | 15 |
| State | TX |
| Symbol | CGON |
| Target High Price | 108.0 |
| Target Low Price | 79.0 |
| Target Mean Price | 91.07692 |
| Target Median Price | 90.0 |
| Total Cash | 1,028,278,016 |
| Total Cash Per Share | 11.601 |
| Total Debt | 8,819,000 |
| Total Revenue | 6,228,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.69 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 60.04755 |
| Two Hundred Day Average Change | 14.292446 |
| Two Hundred Day Average Change Percent | 0.23801881 |
| Type Disp | Equity |
| Volume | 612,555 |
| Website | https://cgoncology.com |
| Zip | 75,247 |